Labisan vs Abreva: preventing cold sores vs treating them

Pricing

Feature comparison

When to pick Labisan

• You get recurring cold sores triggered by sun exposure, skiing, beach days, or any high-UV environment and want to stop the outbreak cycle at the UV trigger rather than treat lesions after they appear.
• You want a daily-wear lip balm with EU pharmaceutical-grade actives: 22% zinc oxide for SPF 20 mineral protection, manuka oil for antimicrobial barrier support, and graviola fruit extract. Not a medicated cream you pull out when it is already too late.
• You are building a prevention stack and want to combine topical mineral UV protection with a high-potency graviola immune support capsule (22:1 fruit water-extract concentrate, 274mg per capsule equivalent to 6028mg raw fruit, 8000mg daily bioactive payload at 3 caps).

When the competitor is the better fit

• You have an active cold sore right now and need an FDA-approved OTC antiviral. Docosanol 10% applied at the first tingling stage is clinically shown to reduce outbreak duration. Labisan does not treat active lesions.
• Your dermatologist or GP has specifically recommended docosanol as part of a reactive treatment protocol and prevention is not the current priority.

FAQs

Abreva contains docosanol 10%, a fatty alcohol that blocks HSV-1 from fusing with healthy lip cells once an outbreak has already started. It is a reactive treatment. Labisan is a preventive daily-wear SPF 20 mineral lip balm with 22% zinc oxide. Zinc oxide physically scatters UV radiation before it suppresses local immune response in lip tissue and triggers HSV-1 reactivation. One acts after the outbreak begins; the other aims to prevent it from starting.

No. Labisan is not an antiviral and does not claim to treat active herpes labialis lesions. If you have an outbreak right now, an OTC treatment like Abreva or a prescription antiviral (acyclovir, valacyclovir) is the appropriate intervention. Once the outbreak resolves, daily Labisan use targets the UV reactivation trigger to reduce the frequency of future outbreaks.

HSV-1 lives latent in the trigeminal nerve ganglia. UV radiation suppresses local innate immune response in lip tissue, which allows the virus to travel down nerve pathways and replicate. This is why many people get cold sores exclusively after beach trips, ski days, or prolonged sun exposure. SPF 20 mineral protection via zinc oxide 22% directly addresses this mechanism. Abreva does nothing to interrupt the UV trigger.

Docosanol is a saturated C22 fatty alcohol that integrates into cell membranes and prevents HSV-1 glycoprotein fusion, limiting viral spread from cell to cell. It is most effective when applied at the prodromal (tingling) stage before a visible lesion appears. It has no preventive function, provides no UV protection, and does not address why the virus reactivated. If the UV trigger is not blocked, the same cycle repeats after each treatment course.

Yes, and it makes clinical sense to stack them at different phases. During an active outbreak, apply Abreva as directed to the lesion. Switch to Labisan as your daily lip balm once healed to address the UV trigger before the next reactivation event. They do not compete; they operate at different points in the herpes labialis lifecycle.

Most graviola supplements use dried leaf powder with minimal concentration of bioactive acetogenins. Labisan's capsules use a 22:1 fruit water-extract: each 274mg capsule delivers the bioactive equivalent of 6028mg raw graviola fruit. At three capsules per day, that is an 8000mg daily bioactive payload. The formula is Austrian pharmaceutical grade, vegan, non-GMO, and gluten free. Leaf powder products at a similar capsule weight deliver a fraction of that concentration.